$IVVD
Invivyd, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023041352 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.89M $10.11M
YoY Change -2.38% -30.87%
% of Gross Profit
Research & Development $25.57M $43.62M
YoY Change -15.12% 17.48%
% of Gross Profit
Depreciation & Amortization $120.0K $120.0K
YoY Change 2300.0%
% of Gross Profit
Operating Expenses $43.06M $53.88M
YoY Change -9.02% 4.11%
Operating Profit -$43.06M -$53.88M
YoY Change -9.02% 4.11%
Interest Expense $1.900M $1.600M
YoY Change 1500.0%
% of Operating Profit
Other Income/Expense, Net $3.620M $3.647M
YoY Change 61.32% 380.5%
Pretax Income -$39.44M -$50.23M
YoY Change -12.53% -1.49%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$39.44M -$50.23M
YoY Change -12.52% -1.49%
Net Earnings / Revenue
Basic Earnings Per Share -$0.36 -$0.46
Diluted Earnings Per Share -$0.36 -$0.46
COMMON SHARES
Basic Shares Outstanding 109.8M 109.5M
Diluted Shares Outstanding 109.8M 109.5M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $264.9M $298.4M
YoY Change -36.73% -37.16%
Cash & Equivalents $181.8M $121.9M
Short-Term Investments $83.06M $176.5M
Other Short-Term Assets $4.500M $11.10M
YoY Change 114.29% 71.4%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $270.1M $310.0M
YoY Change -35.93% -35.6%
LONG-TERM ASSETS
Property, Plant & Equipment $2.002M $2.123M
YoY Change 40.1% 2232.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $187.0K $291.0K
YoY Change -20.76% -2.68%
Total Long-Term Assets $4.814M $5.428M
YoY Change 52.78% 66.96%
TOTAL ASSETS
Total Short-Term Assets $270.1M $310.0M
Total Long-Term Assets $4.814M $5.428M
Total Assets $274.9M $315.4M
YoY Change -35.28% -34.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.168M $4.112M
YoY Change -45.33% -71.11%
Accrued Expenses $15.96M $26.74M
YoY Change -44.92% -49.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.79M $32.51M
YoY Change -41.92% -52.12%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $700.0K $1.300M
YoY Change
Total Long-Term Liabilities $700.0K $1.300M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $26.79M $32.51M
Total Long-Term Liabilities $700.0K $1.300M
Total Liabilities $28.42M $33.85M
YoY Change -39.92% -51.48%
SHAREHOLDERS EQUITY
Retained Earnings -$658.4M -$619.0M
YoY Change 34.67% 39.48%
Common Stock $904.9M $900.6M
YoY Change 4.46% 4.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $246.5M $281.6M
YoY Change
Total Liabilities & Shareholders Equity $274.9M $315.4M
YoY Change -35.28% -34.91%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$39.44M -$50.23M
YoY Change -12.52% -1.49%
Depreciation, Depletion And Amortization $120.0K $120.0K
YoY Change 2300.0%
Cash From Operating Activities -$35.35M -$37.39M
YoY Change -37.03% -34.85%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $95.13M $32.59M
YoY Change -167.78%
Cash From Investing Activities $95.14M $32.59M
YoY Change -167.56% -191805.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 90.00K 270.0K
YoY Change -64.0% 264.86%
NET CHANGE
Cash From Operating Activities -35.35M -37.39M
Cash From Investing Activities 95.14M 32.59M
Cash From Financing Activities 90.00K 270.0K
Net Change In Cash 59.88M -4.530M
YoY Change -130.44% -92.1%
FREE CASH FLOW
Cash From Operating Activities -$35.35M -$37.39M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$35.35M -$37.39M
YoY Change -37.56% -34.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001832038
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40703
dei Entity Registrant Name
EntityRegistrantName
INVIVYD, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1403134
dei Entity Address Address Line1
EntityAddressAddressLine1
1601 Trapelo Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 178
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
819-0080
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
IVVD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
109755624
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
121947000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92076000
CY2023Q2 us-gaap Marketable Securities
MarketableSecurities
176483000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
279915000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11556000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4926000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
309986000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
376917000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2123000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2282000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3014000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3777000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
291000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
191000
CY2023Q2 us-gaap Assets
Assets
315414000
CY2022Q4 us-gaap Assets
Assets
383167000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4112000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1517000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26744000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21911000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1611000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1559000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
38000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
44000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
32505000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25031000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1346000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2165000
CY2023Q2 ivvd Early Exercise Liability
EarlyExerciseLiability
0
CY2022Q4 ivvd Early Exercise Liability
EarlyExerciseLiability
1000
CY2023Q2 us-gaap Liabilities
Liabilities
33851000
CY2022Q4 us-gaap Liabilities
Liabilities
27197000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109570333
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109570333
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109044046
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109044046
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
11000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
900549000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
889657000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-22000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-272000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-618975000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-533426000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
281563000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
355970000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
315414000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
383167000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43618000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37129000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70819000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
129164000
CY2023Q2 ivvd Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
150000
CY2022Q2 ivvd Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0
ivvd Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
975000
ivvd Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10107000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14620000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21152000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
23324000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
53875000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
51749000
us-gaap Operating Expenses
OperatingExpenses
92946000
us-gaap Operating Expenses
OperatingExpenses
152488000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-53875000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-51749000
us-gaap Operating Income Loss
OperatingIncomeLoss
-92946000
us-gaap Operating Income Loss
OperatingIncomeLoss
-152488000
CY2023Q2 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
3647000
CY2022Q2 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
759000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
7397000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
832000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3647000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
759000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7397000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
832000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-50228000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-50990000
us-gaap Net Income Loss
NetIncomeLoss
-85549000
us-gaap Net Income Loss
NetIncomeLoss
-151656000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
93000
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
250000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
8000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50135000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50990000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-85299000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-151648000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.40
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109450071
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109450071
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108166890
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108166890
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109119630
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109119630
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108019051
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108019051
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
558019000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2022Q1 ivvd Exercise Of Stock Options
ExerciseOfStockOptions
47000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1983000
CY2022Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
8000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-100666000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
459392000
CY2022Q2 ivvd Exercise Of Stock Options
ExerciseOfStockOptions
76000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6361000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-50990000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
414839000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
355970000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2023Q1 ivvd Exercise Of Stock Options
ExerciseOfStockOptions
459000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5400000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
83000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
157000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-35321000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
326749000
CY2023Q2 ivvd Exercise Of Stock Options
ExerciseOfStockOptions
215000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4677000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
56000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
93000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-50228000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
281563000
us-gaap Profit Loss
ProfitLoss
-85549000
us-gaap Profit Loss
ProfitLoss
-151656000
us-gaap Share Based Compensation
ShareBasedCompensation
10077000
us-gaap Share Based Compensation
ShareBasedCompensation
8344000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4564000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-194000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
763000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
211000
us-gaap Depreciation
Depreciation
241000
us-gaap Depreciation
Depreciation
9000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6630000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-18825000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
100000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-2998000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2629000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8449000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5334000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3653000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-767000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-214000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-6000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
58000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-6000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78572000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-116441000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
91202000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
199448000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
49000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
615000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
107631000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
48983000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
674000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
123000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
139000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
4000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
812000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
119000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
29871000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-67339000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92076000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
542224000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121947000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
474885000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1728000
ivvd Operating Lease Right Of Use Asset Recognized
OperatingLeaseRightOfUseAssetRecognized
0
ivvd Operating Lease Right Of Use Asset Recognized
OperatingLeaseRightOfUseAssetRecognized
1344000
us-gaap Net Income Loss
NetIncomeLoss
-85500000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-619000000.0
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and related prepaid or accrued costs and stock-based compensation expense. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ materially from those estimates or assumptions.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is monitoring the potential impact of the COVID-19 pandemic on its business and condensed consolidated financial statements. The Company is not aware of any specific event or circumstance that would require any update to its estimates or judgments reflected in these condensed consolidated financial statements or a revision of the carrying value of its assets or liabilities as of the issuance date of these condensed consolidated financial statements. These estimates may change as new events occur and additional information is obtained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
ivvd Annual Gross Revenue
AnnualGrossRevenue
1235000000
CY2023Q2 us-gaap Convertible Debt
ConvertibleDebt
1000000000.0
us-gaap Adjustment For Amortization
AdjustmentForAmortization
176509000
ivvd Unrealized Gain On Marketable Securities
UnrealizedGainOnMarketableSecurities
80000
ivvd Unrealized Loss On Marketable Securities
UnrealizedLossOnMarketableSecurities
106000
us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
176483000
CY2022 us-gaap Adjustment For Amortization
AdjustmentForAmortization
280187000
CY2022 ivvd Unrealized Gain On Marketable Securities
UnrealizedGainOnMarketableSecurities
52000
CY2022 ivvd Unrealized Loss On Marketable Securities
UnrealizedLossOnMarketableSecurities
324000
CY2022 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
279915000
CY2023Q2 ivvd Available For Sale Marketable Securities
AvailableForSaleMarketableSecurities
0
CY2022Q4 ivvd Available For Sale Marketable Securities
AvailableForSaleMarketableSecurities
0
CY2023Q2 ivvd Fair Value Transfers Between Levels Transfers Amount
FairValueTransfersBetweenLevelsTransfersAmount
0
CY2022Q2 ivvd Fair Value Transfers Between Levels Transfers Amount
FairValueTransfersBetweenLevelsTransfersAmount
0
CY2023Q2 ivvd Prepaid External Research Development And Manufacturing Expense Current
PrepaidExternalResearchDevelopmentAndManufacturingExpenseCurrent
8261000
CY2022Q4 ivvd Prepaid External Research Development And Manufacturing Expense Current
PrepaidExternalResearchDevelopmentAndManufacturingExpenseCurrent
843000
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
1067000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2392000
CY2023Q2 ivvd Prepaid Compensation And Related Expenses
PrepaidCompensationAndRelatedExpenses
1754000
CY2022Q4 ivvd Prepaid Compensation And Related Expenses
PrepaidCompensationAndRelatedExpenses
1314000
CY2023Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
474000
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
377000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11556000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4926000
CY2023Q2 ivvd Accrued External Research Development And Manufacturing Expenses Current
AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent
22718000
CY2022Q4 ivvd Accrued External Research Development And Manufacturing Expenses Current
AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent
13955000
CY2023Q2 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
1351000
CY2022Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
1153000
CY2023Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2512000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5985000
CY2023Q2 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
163000
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
818000
CY2023Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
26744000
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
21911000
ivvd Quarterly Fee
QuarterlyFee
1300000
ivvd Delivery Fee
DeliveryFee
200000
ivvd Completion Fee
CompletionFee
200000
ivvd Exercise Fee
ExerciseFee
1000000.0
CY2022Q3 ivvd Acquired In Process Research And Development Expense
AcquiredInProcessResearchAndDevelopmentExpense
3000000.0
CY2023Q2 ivvd Accrued Upfront Fee
AccruedUpfrontFee
200000
CY2023Q1 us-gaap Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
400000
CY2023Q2 us-gaap Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
200000
ivvd Royalty Based On Net Sales Of Licensed Products Percentage
RoyaltyBasedOnNetSalesOfLicensedProductsPercentage
0.010
us-gaap Royalty Expense
RoyaltyExpense
0
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.48
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6824712
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q3 ivvd Lessee Operating Lease Total Lease Space
LesseeOperatingLeaseTotalLeaseSpace
9600
CY2021Q3 us-gaap Sale Leaseback Transaction Monthly Rental Payments
SaleLeasebackTransactionMonthlyRentalPayments
400000
CY2022Q2 us-gaap Sale Leaseback Transaction Monthly Rental Payments
SaleLeasebackTransactionMonthlyRentalPayments
700000
CY2022Q3 us-gaap Sale Leaseback Transaction Monthly Rental Payments
SaleLeasebackTransactionMonthlyRentalPayments
1300000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
430000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
161000
us-gaap Operating Lease Cost
OperatingLeaseCost
860000
us-gaap Operating Lease Cost
OperatingLeaseCost
266000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
11000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
8000
us-gaap Variable Lease Cost
VariableLeaseCost
23000
us-gaap Variable Lease Cost
VariableLeaseCost
16000
CY2023Q2 us-gaap Lease Cost
LeaseCost
441000
CY2022Q2 us-gaap Lease Cost
LeaseCost
169000
us-gaap Lease Cost
LeaseCost
883000
us-gaap Lease Cost
LeaseCost
282000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
432000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
176000
us-gaap Operating Lease Payments
OperatingLeasePayments
864000
us-gaap Operating Lease Payments
OperatingLeasePayments
276000
CY2023Q2 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
867000
CY2023Q2 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
1521000
CY2023Q2 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
430000
CY2023Q2 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
328000
CY2023Q2 us-gaap Purchase Obligation
PurchaseObligation
3146000
CY2023Q2 ivvd Present Value Adjustment
PresentValueAdjustment
-189000
CY2023Q2 ivvd Present Value Of Operating Lease Liability
PresentValueOfOperatingLeaseLiability
2957000
us-gaap Subordinated Borrowing Interest Rate
SubordinatedBorrowingInterestRate
0.060
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M12D
us-gaap Subordinated Borrowing Interest Rate
SubordinatedBorrowingInterestRate
0.060
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M12D
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1600000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1300000
CY2022Q4 ivvd Cash Fees
CashFees
3000000.0
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
107800000
CY2022Q2 us-gaap Purchase Obligation
PurchaseObligation
159400000
CY2023Q2 us-gaap Convertible Preferred Stock Shares Reserved For Future Issuance
ConvertiblePreferredStockSharesReservedForFutureIssuance
43638367
CY2022Q3 us-gaap Partners Capital Account Public Sale Of Units Net Of Offering Costs
PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts
400000000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
23239391
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.01
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1594000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4616889
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.85
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
678643
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.78
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
5356389
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.78
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
21821248
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.92
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
389000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
21821248
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.92
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y2M12D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
389000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7115594
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.69
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M6D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
199000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.18
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.88
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
400000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
600000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
360333
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
75165
ivvd Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod
253402
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
31766
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4677000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6361000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10077000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8344000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
42700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2021Q3 ivvd Percentage Of Total Number Of Shares Of Common Stock Outstanding
PercentageOfTotalNumberOfSharesOfCommonStockOutstanding
0.01
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
2685546
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-50228000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-50990000
us-gaap Net Income Loss
NetIncomeLoss
-85549000
us-gaap Net Income Loss
NetIncomeLoss
-151656000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109450071
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108166890
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109119630
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108019051
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.40
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28677726
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20416527

Files In Submission

Name View Source Status
0000950170-23-041352-index-headers.html Edgar Link pending
0000950170-23-041352-index.html Edgar Link pending
0000950170-23-041352.txt Edgar Link pending
0000950170-23-041352-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ivvd-20230630.htm Edgar Link pending
ivvd-20230630.xsd Edgar Link pending
ivvd-ex10_1.htm Edgar Link pending
ivvd-ex31_1.htm Edgar Link pending
ivvd-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
ivvd-20230630_lab.xml Edgar Link unprocessable
ivvd-20230630_pre.xml Edgar Link unprocessable
ivvd-20230630_htm.xml Edgar Link completed
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ivvd-20230630_cal.xml Edgar Link unprocessable
ivvd-20230630_def.xml Edgar Link unprocessable